Moexipril

Excessive activation of the renin-angiotensin-aldosterone system (RAAS) is one of the core pathological mechanisms for the progression of hypertension and target organ damage. As a third-generation long-acting non-sulfhydryl angiotensin-converting enzyme inhibitor (ACEI), moexipril exerts a stable antihypertensive effect by blocking the conversion of angiotensin I to angiotensin II which has a vasoconstrictive effect, and simultaneously inhibiting the degradation of bradykinin. It is clinically mainly used for the treatment of essential hypertension, and can also be safely used in hypertensive patients complicated with left ventricular hypertrophy and renal insufficiency (creatinine clearance ≥ 30ml/min). Both monotherapy and combination therapy with diuretics or calcium channel blockers can achieve ideal antihypertensive effects. Patients only need to take it once a day to maintain a stable plasma concentration for 24 hours, with high medication compliance.

The overall global market size of ACEI antihypertensive drugs is stable at around USD 18 billion. With the advantages of dual-channel metabolism through the liver and kidney functions and a lower incidence of dry cough adverse reactions than first-generation ACEIs, moexipril accounts for approximately 2.7% of the long-acting antihypertensive drug market segment, with a market growth rate maintained at 3.2% in the past three years. At present, multiple generic pharmaceutical companies have obtained marketing approval in the US and European markets, while the domestic market is still dominated by the original research drug. No domestic generic drug has been approved yet, and it is not included in the scope of the national centralized volume-based procurement. The gap between market supply and demand continues to widen as the prevalence of hypertension increases year by year.

The original research company of moexipril is Bristol-Myers Squibb in the United States, with the original trade name Univasc. The core compound patent expired in 2002 in the United States, and the core patent in the European Union expired in 2003. The main dosage form approved for the original research drug is tablets, with specifications of 7.5mg and 15mg. Its tablets have been included in the FDA Reference Listed Drug Catalog, but have not been included in China's *Catalog of Reference Preparations for Chemical Drugs* yet. There are no approved moexipril preparation products marketed in China, and there is no approved moexipril registration number in A status or I status on the API registration platform. (Data as of June 2025, please refer to the official website of CDE for the latest information)

In response to the R&D and quality control needs of moexipril, CATO can provide a full set of impurity reference standards for this API. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products comply with the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, with clear impurity traceability and complete purity verification data, which can meet the use needs of multiple scenarios such as generic drug consistency evaluation, quality research, and stability investigation.